Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05105152 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Feb 28, 2026 to Feb 28, 2028
    • Site contact updated
    v9
  2. Site contact updated
    • Collaborator revised
    v8
  3. Re-verified, no change to tracked fieldsv7
  4. Primary completion date: Feb 29, 2024 to Feb 28, 2026
    • Study completion date: Jan 31, 2039 to Jan 31, 2041
    v6
  5. Re-verified, no change to tracked fieldsv5
Show 3 earlier versionsHide 3 earlier versions
  1. Site contact updatedv4
  2. Eligibility criteria revised
    • Study title expanded, about 3 words
    v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Nov 15, 2021 to Nov 29, 2021
    • Site details revised
    • Collaborator revised
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A phase 1, open-label, non-randomized study enrolling pediatric and young adult patients with relapsed or refractory CD33+ leukemia with and without prior history of allogeneic hematopoietic cell transplantation, to examine the safety and feasibility of administering an autologous T cell product that has been genetically modified to express a Dimerizing Agent Regulated Immunoreceptor Complex (DARIC).
Trial Details
NCT Number NCT05105152
Lead Sponsor Seattle Children's Hospital
Collaborators: Regeneron Pharmaceuticals
Conditions
(from sponsor)		 Acute Myeloid Leukemia, Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse
Related terms Leukemia, Myeloid, Acute
Enrollment 18 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov